Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2021

View Archived Issues

Galectin-3 inhibition by tetrahydropyran-based thiodisaccharide mimics

AEBP1 mRNA found to be associated with diabetic nephropathy

New loci identified for restless legs syndrome

Kymera Therapeutics describes new PROTACs for inflammatory disorders

Nimbus Iaso patents IRE1-targeting compounds

Cytokinetics synthesizes new Nampt activators

Newave Pharmaceutical presents quinuclidinone analogues

New melanocortin receptor modulators presented by Palatin Technologies

Researchers identify MTSS1 as a novel candidate gene for inherited retinal dystrophy

TCMCB-07 attenuates muscle wasting and body weight loss in murine models of cancer cachexia

IPO8 gene variants identified in Loyes-Dietz-like syndrome

Data unveil NLGN3 as a candidate gene for GnRH deficiency

New loci discovered for genetic disorders

Discovery of novel GluN2B PAMs as potential therapeutics for Alzheimer's disease

New compounds reduce intracellular c-di-GMP content in Pseudomonas aeruginosa

Discovery of novel potent and reversible MAGL inhibitors

Innovent licenses rights to GenFleet's KRAS G12C inhibitor GFH-925

Brickell licenses rights to Voronoi's DYRK1A inhibitors

Alligator and Scandion conclude collaboration evaluating mitazalimab with SCO-101 and chemotherapy

Bristol Myers Squibb exercises option to Evotec's EVT-8683

New Drosophila model casts light on cancer cachexia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...